Picton Mahoney Asset Management’s Akero Therapeutics AKRO Stock Holding History

Picton Mahoney Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-55,993	Closed	-$2.66M	–	1205
2025 Q3	$2.66M	Sell	55,993 -293	-0.5%	-$14.2K	0.02%	337
2025 Q2	$3M	Buy	56,286 +22,675	+67%	+$1.03M	0.03%	301
2025 Q1	$1.36M	Buy	+33,611	New	+$1.42M	0.02%	281

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Picton Mahoney Asset Management's AKRO Position: Q4 2025 in Review

Picton Mahoney Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 55,993 shares — an estimated $2.66M sold.

Picton Mahoney Asset Management first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $3M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Picton Mahoney Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Picton Mahoney Asset Management sold 55,993 Akero Therapeutics shares in Q4 2025, an estimated $2.66M.
Picton Mahoney Asset Management first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Picton Mahoney Asset Management's Akero Therapeutics position peaked at $3M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.